Published in PLoS One on July 10, 2017
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 38.62
PANTHER: a library of protein families and subfamilies indexed by function. Genome Res (2003) 21.64
Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics (2006) 17.28
Annotation of functional variation in personal genomes using RegulomeDB. Genome Res (2012) 11.47
HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res (2011) 11.03
SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res (2005) 7.34
Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature (1990) 6.59
Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell (2010) 4.45
Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet (2008) 3.54
Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res (2003) 3.07
Prediction of protein stability changes for single-site mutations using support vector machines. Proteins (2006) 3.00
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
A molecular model of MHC class-I-restricted antigen processing. Immunol Today (1992) 2.55
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47
Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol (1994) 2.08
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
A three-state prediction of single point mutations on protein stability changes. BMC Bioinformatics (2008) 1.73
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet (2010) 1.69
HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo. J Invest Dermatol (2011) 1.68
The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol (1995) 1.65
Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest (2007) 1.56
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol (2012) 1.52
Vitiligo: clinical findings in 1436 patients. J Dermatol (1999) 1.51
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res (2012) 1.48
Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol (2011) 1.45
Specificity of the proteasome and the TAP transporter. Curr Opin Immunol (1999) 1.18
Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol (1996) 1.17
Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie (2001) 1.17
Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol (2010) 1.14
Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol (2006) 1.09
Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet (1995) 1.09
Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol (2011) 1.08
A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol (2012) 1.06
The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. Br J Dermatol (2008) 0.99
Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. J Clin Invest (1993) 0.97
A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett (1997) 0.95
Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res (2013) 0.95
Interleukin-4 genetic variants correlate with its transcript and protein levels in patients with vitiligo. Br J Dermatol (2012) 0.93
Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol (2011) 0.93
Association of a new allele of the TAP2 gene, TAP2*Bky2 (Val577), with susceptibility to Sjögren's syndrome. Arthritis Rheum (1997) 0.93
Antigen processing and autoimmunity. Evaluation of mRNA abundance and function of HLA-linked genes. Ann N Y Acad Sci (1998) 0.92
Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun (2003) 0.92
Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol (1997) 0.89
Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol (2014) 0.88
Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res (2004) 0.88
Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One (2012) 0.87
T cell profiles in vitiligo. J Am Acad Dermatol (1986) 0.85
Polymorphism of antigen processing (TAP, LMP) and HLA class II genes in celiac disease. Hum Immunol (1994) 0.84
Association of HLA class I alleles with vitiligo in Chinese Hans. J Dermatol Sci (2004) 0.84
Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype. Genes Immun (2007) 0.84
Genetic sources of population epigenomic variation. Nat Rev Genet (2016) 0.82
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) in isolated vitiligo: a genotype-phenotype correlation. Pigment Cell Melanoma Res (2011) 0.81
Association of generalized vitiligo with MHC class II loci in patients from the Indian subcontinent. J Invest Dermatol (2013) 0.81
Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun Rev (2015) 0.81
Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. J Interferon Cytokine Res (2013) 0.81
Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Br J Dermatol (2013) 0.81
Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J Am Acad Dermatol (1986) 0.80
Vitiligo and alopecia areata: apples and oranges? Exp Dermatol (2013) 0.79
Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol Lett (1998) 0.79
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet (2016) 0.77
Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS One (2014) 0.77
Transporter TAP1-637G and immunoproteasome PSMB9-60H variants influence the risk of developing vitiligo in the Saudi population. Dis Markers (2014) 0.77
Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility. PLoS One (2013) 0.77
[Impact on tyrosinase expression and export from endoplasmic reticulum by inhibition of 26S proteasome]. Zhonghua Yi Xue Za Zhi (2013) 0.76
Association and expression of antigen processing gene PSMB8 coding for Low Molecular Mass Protease 7 (LMP7) with Vitiligo in North India: case-control study. Br J Dermatol (2017) 0.76
Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets. BMC Genomics (2017) 0.75
Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol (2014) 0.88
Increased Tumor Necrosis Factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One (2012) 0.87
Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS One (2014) 0.77
Association of Neuropeptide-Y (NPY) and Interleukin-1beta (IL1B), Genotype-Phenotype Correlation and Plasma Lipids with Type-II Diabetes. PLoS One (2016) 0.75
Genetic variations (Arg5Pro and Leu6Pro) modulate the structure and activity of GPX1 and genetic risk for vitiligo. Exp Dermatol (2016) 0.75
Treatment Avenues for Type 2 diabetes and Current perspectives on Adipokines. Curr Diabetes Rev (2017) 0.75